| Supplementary Table. Sensitivity analysis: geometric means and 95% confidence intervals of different tobacco-related metabolites among exclusive daily opiate users and dual users of daily opiates and cigarette, excluding non-daily users of opiates | | | | |
| --- | --- | --- | --- | --- |
|  | | | |
|  | Exclusive daily opiate users  (n=17)\* | Dual users of daily opiates and cigarette (n=27)\* |
| **Polycyclic aromatic hydrocarbons (ng/g creatinine)** | | | | |
| 1-nap | 17579.6(10859.6,28458.0) | 30449.6(21906.6,42324.2) |
| 2-nap | 4287.9(3417.0,5380.8) | 19201.4(15041.2,24512.3) |
| 1-phe | 311.6(240.7,403.4) | 524.8(436.7,630.6) |
| ∑2,3-phe | 3916.3(1978.7,7751.2) | 2370.1(1375.6,4083.5) |
| 2-flu | 667.6(547.7,813.8) | 2096.5(1663.8,2641.9) |
| 3-flu | 1012.3(679.9,1507.2) | 2611.6(1894.8,3599.5) |
| 1-pyr | 1090.6(708.6,1678.5) | 1489(1140.1,1944.6) |
| **Volatile organic compounds (ng/mg creatinine)** | | | | |
| 2MHA | 103.2(52.3,203.6) | 192.7(130.1,285.5) |
| 34MH | 564.9(316.4,1008.3) | 1259.7(864.8,1834.9) |
| AAMA | 279.6(201.5,387.8) | 286.3(214.3,382.5) |
| GAMA | 32.7(22.6,47.3) | 32.7(24.5,43.8) |
| CYHA | 6.2(3.8,10.0) | 34.1(25.1,46.4) |
| CYMA | 25.1(15.3,41.0) | 190.8(144.6,251.8) |
| CEMA | 99.9(82.0,121.7) | 241.2(187.1,310.9) |
| HPMA | 266.3(207.0,342.6) | 1228.3(810.8,1860.9) |
| BMA | 7.8(4.8,12.7) | 6.3(4.5,8.7) |
| MADA | 275.5(229.8,330.2) | 488.6(392.0,609.1) |
| PHGA | 61.8(34.1,112.0) | 98.2(64.1,150.5) |
| PMA | 1.3(0.9,1.9) | 1.9(1.6,2.4) |
| HPM2 | 21.8(17.5,27.2) | 70(54.7,89.6) |
| AMCA | 384.2(278.8,529.6) | 794.4(638.2,988.8) |
| DHBM | 321.9(240.9,430.3) | 447.4(367.6,544.5) |
| MHB3 | 5.3(4.2,6.7) | 33.2(22.4,49.4) |
| HPMM | 373.7(269.9,517.5) | 2024.8(1353.7,3028.6) |
| IPM3 | 3.5(2.3,5.2) | 40(23.3,68.8) |
| TTCA | 10.1(6.8,14.9) | 21.5(13.3,34.6) |
| \*Numbers exclude individuals who reported using opiates on less than 7 days a week in addition to those who had self-reported tobacco status discordant with measured cotinine levels | | |